Stockreport

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

TScan Therapeutics, Inc.  (TCRX) 
PDF Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) pa [Read more]